Vitrolife AB (VITR) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Vitrolife AB stock SEK 45.83, price SEK 120, that is 61.8% below the price, quality 50 out of 100. Rating: strongly overvalued. Calculated from audited financials with 12 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 5, 2026.
How to read this chart
60‑month range kr 84.83 – kr 550.74 · fair‑value band kr 24.69 – kr 74.63 · the kr 120.10 price screens above the kr 45.83 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 5, 2026.
Follow Vitrolife in your weekly email
Every Wednesday you see whether Vitrolife is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Vitrolife AB (publ) provides assisted reproduction products in Europe, the Middle East, Africa, Asia-Pacific, and the Americas.
Show moreShow less
It offers sperm processing, oocyte retrieval needles, micromanipulation pipettes, time-lapse systems, and evaluation tools, laser and imaging systems, IVF media and oil, embryo transfer, cryopreservation, and genomics kits.
The company also provides eWitness and Labware products, such as dishes, pipettes, tubes, and VitroTemp. The company was incorporated in 1989 and is based in Gothenburg, Sweden.
Stock analysis
Vitrolife AB (VITR) currently trades at kr 120.10, while our model-based Fair Value estimate is kr 45.83, 62% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of kr 72.36 per share, and 0 of the 12 models we run sit above the kr 120.10 price.
Bear case: the Earnings-Based group reads lowest at kr 23.53, and 12 of the 12 models stay below the price. Data coverage for this calculation is medium.
Scenario range: kr 24.69 (bear) to kr 74.63 (bull), the price of kr 120.10 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 50/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Vitrolife AB reported revenue of 3.4B SEK in FY2025 versus 1.7B SEK in FY2021, a compound +19.6%/yr. Reported net income was −5.0B SEK in FY2025.
Key figures
Market cap 16.3B SEK (≈ $1.6B) Small · P/S ratio 4.20 · EPS (TTM) kr −36.60 · Dividend yield 0.9% · Net margin −144% · Return on equity −46.3% · Return on assets (EBIT) −1.3% (5-year average) · Operating margin 20.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 25 out of 100 (low confidence).
What moves the price
The share trades about 20% below its 52-week high and 42% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at −62%, VITR screens richer than that median.
Fair Value models
Bearkr 24.69Fair Value kr 45.83Bullkr 74.63
Price kr 120.10 · Downside -61.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.61/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−4.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+22.5%
Start year 2020 (pandemic). Over 10 years: +16.9% a year
Revenue growth 25 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.1%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
33.0% (2019) → 21.7% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+34.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+6.5%
Yearly sales growth analysts expect, extended to five years.
After inflation (Sweden: IMF forecast 2.0% a year to 2030, 2.9% from 2016 to 2025) that is about +31.5% a year for the price and +4.5% for the forecasts.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 320 stocks
Beats the industry median on 1/12 measures
Overall it trails its industry peers.
Valuation
Quality Score50 · Below median
Fair Value upside−61.8% · Below median
Profitability
Return on assets−45.1% · Bottom 25%
Net margin (12 months)−144.1% · Bottom 25%
Operating margin (12 months)20.1% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)5.9% · Below median
Dividend yield (12 months)0.9% · Bottom 25%
Balance sheet
Debt / equity0.19× · Above median
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/B2.06× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Vitrolife AB Fair Value". https://www.fairvalue-calculator.com/stock/VITR
Frequently asked questions
Is Vitrolife AB (VITR) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of kr 45.83 versus a price of kr 120.10, about 62% lower (overvalued).
What is the fair value of VITR?
Our model-based fair value for Vitrolife AB is kr 45.83 (as of Nov 5, 2026), built from audited fundamentals. The current price: kr 120.10.
What is the quality score of VITR?
Vitrolife AB has a Quality Score of 50/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Vitrolife AB (VITR)?
Our model-based price target is the fair value of kr 45.83 (as of Nov 5, 2026) from 12 valuation models. Cautious scenario kr 24.69, optimistic scenario kr 74.63. It is a calculation from audited fundamentals, not an analyst target.
What is the Vitrolife AB stock forecast for 2026?
Our models put fair value at kr 45.83, about 62% lower versus a price of kr 120.10 (overvalued). Cautious scenario kr 24.69, optimistic scenario kr 74.63. The calculation is refreshed regularly with new filings.
What is the revenue of Vitrolife AB (VITR)?
Vitrolife AB reported trailing-twelve-month revenue of about 3.4B SEK (latest available figure, as of Nov 5, 2026).
Does Vitrolife AB pay a dividend?
Vitrolife AB currently shows a dividend yield of 0.92% relative to its recent price (as of Nov 5, 2026).
How much is the dividend of Vitrolife AB (VITR) and when is the ex-dividend date?
Vitrolife AB pays a dividend of kr 1.10 per share a year, a dividend yield of 0.9%. The last ex-dividend date was May 6, 2026. A dividend has been paid every year since at least 2009. Free cash flow covers the dividend 2.50 times. Our assessment: Cash covered. The dividend is fully funded by free cash flow. The payout ratio on earnings is not available for this company.
What growth is priced into Vitrolife AB (VITR)?
For today's price to be fair in a discounted-cash-flow model, Vitrolife AB would have to grow free cash flow by +34.1 % per year for five years (discount rate 12.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +22.5 % per year. As of Nov 5, 2026.
What discount rate (WACC) does the fair value of VITR use?
Our models discount Vitrolife AB at 12.9 %: a base by market capitalisation (small), damped by beta 1.67, country premium for Sweden. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Vitrolife AB that is +34.1 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (12.9 %) and the same formula as our fair value.
How much growth has Vitrolife AB (VITR) delivered so far?
Over the past 5 years revenue at Vitrolife AB grew +22.5 % a year. The price currently implies free-cash-flow growth of +34.1 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Vitrolife AB (VITR) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Vitrolife AB (+34.1 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Vitrolife AB (VITR)?
The free-cash-flow yield on the price is 2.24 %: that much free cash flow Vitrolife AB produces per unit of market value. When it exceeds the discount rate of our models (12.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Vitrolife AB (VITR)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Vitrolife AB it is kr 45.83 per share (as of Nov 5, 2026), against a price of kr 120.10. It is the blended result of 12 valuation models in 5 families (DCF Models, Earnings-Based, Multiples, Growth DCF, Economic Profit).
Is Vitrolife AB stock overvalued or undervalued in 2026?
As of Nov 5, 2026, VITR trades above its calculated fair value: price kr 120.10, fair value kr 45.83, a gap of about −62% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of VITR?
No. The price is what the market pays today (kr 120.10); the fair value is what the company's own numbers justify (kr 45.83). For Vitrolife AB the two are kr 74.27 per share apart. That gap is exactly why we show both numbers side by side.
How much is Vitrolife AB worth?
The market values Vitrolife AB at about 16.3B SEK (market capitalisation, as of Nov 5, 2026). Per share that is kr 120.10; our models calculate a fair value of kr 45.83 per share.
What do the bullish and bearish scenarios say about VITR?
Our models span a range for Vitrolife AB: cautious scenario kr 24.69, base kr 45.83, optimistic kr 74.63 per share (as of Nov 5, 2026, price kr 120.10). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of VITR?
The PEG ratio of Vitrolife AB is 2.02 (P/E divided by earnings growth, as of Nov 5, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Vitrolife AB (VITR)?
Balance-sheet figures for Vitrolife AB (as of Nov 5, 2026): return on equity −46.3%, debt of 0.19 per unit of equity. They feed the Quality Score of 50/100, which measures business quality independently of the share price.
How far is VITR from its 52-week high?
Vitrolife AB trades at kr 120.10, about 20% below its 52-week high of kr 149.46 and 42% above the low of kr 84.83 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of kr 45.83 is for.
Which stocks are comparable to Vitrolife AB?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Vitrolife AB stock attractive at the current price?
The data as of Nov 5, 2026: price kr 120.10, calculated fair value kr 45.83 (−62%), Quality Score 50/100, from 12 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of VITR calculated?
We run Vitrolife AB through 12 models from 5 families: DCF Models, Earnings-Based, Multiples, Growth DCF, Economic Profit. Every model gets the same audited fundamentals; the fair value of kr 45.83 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Vitrolife AB itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Vitrolife AB (VITR)?
The closing price on Nov 6, 2026 was kr 120.10. Our model-based fair value is kr 45.83, about 62% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Vitrolife AB right now?
The price sits above even our optimistic bull case (kr 74.63). The favourable scenario is already priced in. The model range is unusually wide (kr 24.69 to kr 74.63). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid but not exceptional quality (50/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Vitrolife AB
How large is the market capitalisation of Vitrolife AB (VITR)?
The market capitalisation of Vitrolife AB is 16.3B SEK (≈ $1.6B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Vitrolife AB (VITR)?
The price-to-sales ratio of Vitrolife AB is 4.20 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Vitrolife AB (VITR)?
Earnings per share at Vitrolife AB are kr −36.60. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Vitrolife AB (VITR)?
The dividend yield of Vitrolife AB is 0.9%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Vitrolife AB (VITR)?
The net margin of Vitrolife AB is −144% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Vitrolife AB (VITR)?
The return on equity (ROE) of Vitrolife AB is −46.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Vitrolife AB (VITR)?
On an EBIT basis the return on assets of Vitrolife AB is −1.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Vitrolife AB (VITR)?
The operating margin of Vitrolife AB is 20.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Vitrolife AB (VITR)?
Revenue at Vitrolife AB is growing +5.9% versus a year earlier (3y avg +2.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Vitrolife AB (VITR)?
Earnings per share at Vitrolife AB are growing +25.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Vitrolife AB (VITR) carry?
The net debt of Vitrolife AB is 868M SEK (fiscal year 2025, ≈ 2.4 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Vitrolife AB in the live analysis
One click puts Vitrolife AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 5, 2026